Table 4.
Neurological function score of included studies.
| Study reporting mRS | Evaluation timing | mRS | ||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | ||
| Matsukawa et al. (32) | Preoperative | 30 (37.5) | 32 (40) | 15 (18.75) | 0 | 1 (1.25) | 2 (2.5) | 0 |
| Discharge | 36 (45) | 21 (26.25) | 17 (21.25) | 3 (3.75) | 3 (3.75) | 0 | 0 | |
| Follow-up | 49 (61.25) | 19 (23.75) | 9 (11.25) | 2 (2.5) | 1 (1.25) | 0 | 0 | |
| Nurminen et al. (35) | Preoperative | 2 (8.33) | 15 (62.5) | 2 (8.33) | 2 (8.33) | 1 (4.17) | 2 (8.33) | 0 |
| Follow-up | 6 (25) | 6 (25) | 6 (25) | 3 (12.5) | 2 (8.33) | 1 (4.17) | 0 | |
| Morgan et al. (20) | Preoperative | 6 (28.57) | 14 (66.67) | 1 (4.76) | 0 | 0 | 0 | 0 |
| Follow-up | 12 (57.14) | 5 (23.81) | 1 (4.76) | 0 | 0 | 1 (4.76) | 2 (9.52) | |
| Nussbaum et al. (33) | Follow-up | 85 (89.47) | 4 (4.21) | 2 (2.11) | 2 (2.11) | 2 (2.11) | ||
| Other mRS formats | ||||||||
| Dodier et al. (38) | Preoperative | median 2 | ||||||
| Follow-up | Improve/total 36 (97.3) mRS 0–2 36 (97.3) | |||||||
| Cantore et al. (22) | Follow-up | Improve/total 35 (87.5) | ||||||
| Study reporting GOS | Evaluation timing | GR | MD | SD | ||||
| Ishishita et al. (27) | Follow-up | 37 (100) | 0 | 0 | ||||
| Murakami et al. (23) | Follow-up | 23 (79.31) | 2 (6.9) | 4 (13.79) | ||||
Data presented as n (%). mRS, modified Rankin scale; GOS, glasgow outcome scale; GR, good recovery; MD, moderately disabled; SD, severely disabled; NR, non-reported.